Predictors of persistent symptoms and reduced quality of life in treated coeliac disease patients: a large cross-sectional study by Paarlahti, Pilvi et al.
 
 
This document has been downloaded from  
TamPub – The Institutional Repository of University of Tampere 
 
 
Publisher's version 
 
The permanent address of the publication is http://urn.fi/URN:NBN:fi:uta-
201305231100  
  
Author(s):  Paarlahti, Pilvi; Kurppa, Kalle; Ukkola, Anniina; Collin, Pekka; Huhtala, Heidi; Mäki, Markku; Kaukinen, Katri 
Title:  Predictors of persistent symptoms and reduced quality of life in treated coeliac disease patients: a large cross-sectional study 
Year:  2013 
Journal Title:  BMC Gastroenterology 
Vol and 
number:  13 : 75  
Pages:  1-8 
ISSN:  1471-230X 
Discipline:  Internal medicine 
School /Other 
Unit:  School of Medicine; School of Health Sciences 
Item Type:  Journal Article 
Language:  en 
DOI:  http://dx.doi.org/10.1186/1471-230X-13-75  
URN:  URN:NBN:fi:uta-201305231100 
URL:  http://www.biomedcentral.com/1471-230X/13/75  
 
 
 
 
All material supplied via TamPub is protected by copyright and other intellectual 
property rights, and duplication or sale of all part of any of the repository collections 
is not permitted, except that material may be duplicated by you for your research use 
or educational purposes in electronic or print form. You must obtain permission for 
any other use. Electronic or print copies may not be offered, whether for sale or 
otherwise to anyone who is not an authorized user. 
Paarlahti et al. BMC Gastroenterology 2013, 13:75
http://www.biomedcentral.com/1471-230X/13/75RESEARCH ARTICLE Open AccessPredictors of persistent symptoms and reduced
quality of life in treated coeliac disease patients:
a large cross-sectional study
Pilvi Paarlahti1, Kalle Kurppa1, Anniina Ukkola1, Pekka Collin2, Heini Huhtala3, Markku Mäki1 and Katri Kaukinen2,4*Abstract
Background: Evidence suggests that many coeliac disease patients suffer from persistent clinical symptoms and
reduced health-related quality of life despite a strict gluten-free diet. We aimed to find predictors for these
continuous health concerns in long-term treated adult coeliac patients.
Methods: In a nationwide study, 596 patients filled validated Gastrointestinal Symptom Rating Scale and
Psychological General Well-Being questionnaires and were interviewed regarding demographic data, clinical
presentation and treatment of coeliac disease, time and place of diagnosis and presence of coeliac disease-
associated or other co-morbidities. Dietary adherence was assessed by a combination of self-reported adherence
and serological tests. Odds ratios and 95% confidence intervals were calculated by binary logistic regression.
Results: Diagnosis at working age, long duration and severity of symptoms before diagnosis and presence of
thyroidal disease, non-coeliac food intolerance or gastrointestinal co-morbidity increased the risk of persistent
symptoms. Patients with extraintestinal presentation at diagnosis had fewer current symptoms than subjects with
gastrointestinal manifestations. Impaired quality of life was seen in patients with long duration of symptoms before
diagnosis and in those with psychiatric, neurologic or gastrointestinal co-morbidities. Patients with persistent
symptoms were more likely to have reduced quality of life.
Conclusions: There were a variety of factors predisposing to increased symptoms and impaired quality of life in
coeliac disease. Based on our results, early diagnosis of the condition and consideration of co-morbidities may help
in resolving long-lasting health problems in coeliac disease.
Keywords: Coeliac disease, Symptoms, Quality of life, Gluten-free diet, AdultsBackground
At present, the only treatment for coeliac disease is a life-
long gluten-free diet, i.e. exclusion of wheat-, rye- and
barley-containing cereals and food products. Upon
removal of gluten from the diet clinical symptoms are
usually rapidly alleviated, while recovery of the duodenal
mucosa may take several months or even years [1]. The
treatment may also prevent many coeliac disease-
associated complications such as intestinal malignancies
[2]. Notwithstanding these benefits, the stigma of a* Correspondence: katri.kaukinen@uta.fi
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reproduction in any medium, provided the orchronic disorder and the need for major dietary restric-
tions increases the self-perceived burden of illness and
may impair patients’ quality of life [3,4]. The symptoms
may also remain despite a long-term and strict diet [5,6].
As a result, in some studies even well-treated coeliac
patients have failed to attain well-being similar to that of
the population in general [7,8], albeit that there are also
contradictory results [9,10]. To improve the situation,
knowledge of the factors underlying these persistent
health concerns in coeliac patients is required. Thus
far, only a limited number of studies have investigated
this issue [11]; data are scant, particularly in screen-
detected patients and in subjects with extraintestinal
presentation [9,12].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Paarlahti et al. BMC Gastroenterology 2013, 13:75 Page 2 of 8
http://www.biomedcentral.com/1471-230X/13/75The aim of this large nationwide study was to find pre-
dictors of persistent gastrointestinal symptoms and
reduced health-related quality of life in long-term
treated adult coeliac patients. Particular attention was
devoted to aspects such as duration and severity of
symptoms before diagnosis and presence of coeliac
disease-associated and other co-morbidities.
Methods
Study design and participants
The trial was conducted at the Department of Gastro-
enterology and Alimentary Tract Surgery, Tampere
University Hospital. Adult volunteers were recruited by
a nationwide search using newspaper advertisements
and via national and local coeliac disease societies. The
study cohort comprised a total of 596 adults (age > 18
years) with biopsy-proven coeliac disease. All coeliac
diagnoses and other relevant medical data (see below)
were confirmed from the patients’ medical records. Sub-
jects who had been on a gluten-free diet less than one
year, had biopsy-proven refractory coeliac disease, or
whose coeliac disease diagnosis could not be verified
were excluded from the study.
All eligible subjects filled self-administered, validated
and structured gastrointestinal symptom and corre-
sponding health-related quality of life questionnaires.
Next, to reveal factors associated with persistent symp-
toms and poor quality of life, the participants were
interviewed by a physician or study nurse with expertise
in coeliac disease. They were asked to report their
demographic data and family history of coeliac disease,
clinical presentation of the condition, time and place of
diagnosis (primary, secondary or tertiary health care),
dietary counseling and regular follow-up, adherence to
the gluten-free diet, possible consumption of oats and
duration of diet. Furthermore, the presence of coeliac
disease-associated or other significant co-morbidities
such as autoimmune thyroidal disease or type 1 diabetes,
was inquired after.
Clinical presentation at diagnosis was further catego-
rized into gastrointestinal (any kind of gastrointestinal
symptom or signs of malabsorption), extraintestinal (e.g.
dermatitis herpetiformis, neurological symptoms or arth-
ralgia) and screen-detected (subjects identified by screen-
ing in at-risk groups). Duration of symptoms was defined
as first experienced symptom until diagnosis, and was di-
vided into three subgroups as follows: no symptoms,
symptoms 10 years or less and symptoms more than 10
years. Further, the self-perceived severity of the symptoms
was asked and divided into three subgroups as follows: no
symptoms, moderate symptoms and severe symptoms.
Altogether 110 healthy subjects (81% females, median
age 49 (range 24–87) years) having no first-degree rela-
tives with coeliac disease were used as a non-coeliaccontrol group. The controls were recruited from the
close neighborhood and among friends of the coeliac
patients.
All participants gave written informed consent. The
study protocol was approved by the Ethical Committee
of Tampere University Hospital.
Health-related quality of life and gastrointestinal
symptoms
The current self-perceived gastrointestinal symptoms and
health-related quality of life of the participants were evalu-
ated by structured and well-validated questionnaires
widely applied in coeliac disease research [7,12-15]. The
Gastrointestinal Symptom Rating Scale (GSRS) [16,17]
was used to evaluate gastrointestinal symptoms. The ques-
tionnaire comprises 15 separate items covering five differ-
ent sub-dimensions: diarrhoea, indigestion, constipation,
abdominal pain and reflux. The scoring is based on a
7-grade Likert scale in which 1 point indicates no
symptoms and 7 points the most severe gastrointes-
tinal symptoms. Values for each sub-dimension score
are calculated as a mean of the relevant items. The
total GSRS score is calculated as a mean value of all 15
items and may thus also gain values between 1 to 7
points. Patients with a score higher than 1 standard
deviation (SD, 0.66 points) compared to the control
mean were considered to have increased gastrointes-
tinal symptoms [18-20]. The threshold score for
increased symptoms was therefore 2.55 points.
The Psychological General Well-Being (PGWB) ques-
tionnaire [12,13,15,21] was used to measure health-
related quality of life. This survey consists of 22 separate
items covering six different sub-dimensions: anxiety,
depression, well-being, self-control, general health and
vitality. The scoring is based on a 6-grade Likert scale in
which higher scores indicate better quality of life. The
value of the total PGWB score may range from a mini-
mum of 22 to maximum 132. The sub-scores are calcu-
lated as a sum of the items in each sub-dimension in
question. Subjects with a score less than 1 SD (12.1
points) compared to the control mean were considered
to have reduced quality of life [18-20], so the threshold
score was 93.1 points.
Adherence to the gluten-free diet
The possible consumption of gluten-containing products
was assessed by a combination of self-reported adherence
and coeliac disease serology. Participants were rated
strictly adherent if they reported being on a strict gluten-
free diet in dietary interview and were found to be nega-
tive for serum endomysial (EmA) and transglutaminase 2
(TG2-ab) antibodies.
Serum IgA class EmA were measured by an indirect
immunofluorescence method with human umbilical cord
Table 1 Demographic data and clinical characteristics of
the 596 coeliac disease patients
Female, n (%) 452 (76)
Current age, median (range), years 55 (19–92)
Age at diagnosis, median (range), years 44 (1–82)
Site of diagnosis, n (%)
Primary care 149 (25)
Secondary or tertiary care 446 (75)
Presenting symptom at time of diagnosis, n (%)
Gastrointestinal 1 410 (69)
Extraintestinal 2 95 (16)
Screen-detected 3 91 (15)
Coeliac disease in family, n (%) 372 (62)
Coeliac disease-associated disorders, n (%)
Type 1 diabetes mellitus 14 (2)
Thyroid disease 107 (18)
Gluten-free diet, n (%)
Strict 520 (88)
Occasional gluten 76 (12)
No diet 0
Consumption of oats, n (%) 487 (82)
Duration of gluten-free diet, median (range), years 10 (1–53)
1Stomach pain, diarrhoea, constipation, heartburn, flatulence, swelling,
anaemia, malabsorption.
2Dermatitis herpetiformis, tiredness, joint pains, neurologic symptoms,
gynaecologic problems.
3Coeliac disease in relatives, presence of autoimmune disorder.
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linked immunosorbent assay (QUANTA Lite h-tTG IgA,
INOVA Diagnostics, San Diego, CA, USA). A dilution of
1: ≥5 for EmA was considered positive and positive sam-
ples were further diluted 1:50, 1:100, 1:200, 1:500, 1:1000,
1:2000 and 1:4000. In TG2-ab unit values ≥30 U/I were
considered positive. In cases known to involve selective
IgA deficiency, the corresponding IgG-class antibodies
were applied.
Statistics
Categorical data were described using percentages and
quantitative data using medians with range. Binary logis-
tic regression analysis was used to identify factors associ-
ated with reduced quality of life. Results are presented as
odds ratios (OR) with 95% confidence intervals (CI). A
p-value ≤ 0.05 was considered statistically significant.
T-test was used to compare the GSRS and PGWB mean
scores between coeliac patients and healthy controls.
If a patient failed to answer on one or two items in the
PGWB or GSRS questionnaire, the missing answer was
replaced by the mean value of the other scores for the
same subject. If more than two answers were missing
the questionnaire was disqualified. All statistical data
were analyzed by the Predictive Analytic SoftWare for
Windows version 19 (IBM Corporation, Armonk, NY,
USA).
Results
Clinical characteristics of the study cohort are shown in
Table 1. In total, 69% of the subjects were diagnosed on
the basis of classical gastrointestinal presentation and
31% on the basis of extraintestinal symptoms or by
screening in at-risk coeliac disease groups. Altogether
88% of the subjects were strictly adherent; none reported
totally unrestricted gluten consumption and 82% used
oats as a regular part of their diet. Lactose intolerance
was present in 17%, food allergy in 5% and fructose
intolerance in none of the participants. Further, 6% of
the subjects had reflux disease, 4% gastritis, 2% diver-
ticulosis and 2% cholelithiasis. The most common psy-
chiatric disorder was depression, with a prevalence of 2%
(78% of subjects with psychiatric diagnosis).
The mean total GSRS score was 2.1 (range 1.0- 4.8) in
the study group and 1.9 (range 1.0- 4.2) in the controls.
The score was higher than 1 SD compared to the control
mean in 25% of the participants. There was no significant
association between the persistent gastrointestinal symp-
toms and gender or current age, but patients diagnosed
between the age of 25 and 60 years had more persistent
symptoms than those diagnosed at younger or older age
(Table 2). Further, subjects who had suffered from moder-
ate or severe symptoms at the time of the diagnosis or had
had symptoms more than 10 years before it had morecurrent gastrointestinal symptoms than initially asymp-
tomatic patients. Patients diagnosed on extraintestinal
symptoms had fewer current symptoms than those with
gastrointestinal presentation (Table 2). The presence of
thyroid disease, non-coeliac food intolerance, other
gastrointestinal disease and any coeliac disease-related co-
morbidity also increased the risk of persistent symptoms.
None of the other variables examined, including dietary
non-adherence and consumption of oats, was associated
with persistent symptoms. The GSRS mean total score
was significantly higher in the study participants than in
control subjects (p= 0.003).
The mean PGWB total score was 102.8 (range 29.0-
132.0) in the study group and 105.3 (range 65.0-126.0)
in the controls. Altogether 25% of the participants had
the score lower than 1 SD compared to the control
mean. Reduced health-related quality of life was seen in
patients with manifest symptoms prior to diagnosis
compared with asymptomatic subjects; the difference
was evident in particular among those with symptoms
for more than 10 years. Further, subjects with any psy-
chiatric co-morbidity had reduced quality of life
(Table 3). A similar trend was observed in patients with
neurological disease and gastrointestinal co-morbidity,
Table 2 Factors associated with persistent gastrointestinal symptoms* in treated coeliac disease patients
Variable n Symptoms, % OR 95% CI p-value
Gender Male 144 22 1.00
Female 452 26 1.26 0.80-1.97 0.317
Present age, years < 25 12 20 1.00
25-60 380 24 1.25 0.26-6.01 0.778
> 60 204 27 1.51 0.31-7.33 0.611
Age at diagnosis, years < 25 79 13 1.00
25-60 457 27 2.86 1.38-5.91 0.050
> 60 60 20 1.99 0.77-5.10 0.154
Symptoms at diagnosis Gastrointestinal 410 27 1.00
Extraintestinal 95 17 0.56 0.31-1.00 0.050
Screen-detected 91 24 0.88 0.52-1.49 0.636
Duration of symptoms before diagnosis, years No symptoms 37 11 1.00
≤ 10 350 22 2.33 0.80-6.77 0.121
> 10 182 34 4.16 1.41-12.28 0.010
Severity of symptoms at diagnosis No symptoms 62 13 1.00
Moderate 457 25 2.27 1.05-4.91 0.037
Severe 77 31 3.06 1.26-7.41 0.013
Site of diagnosis Hospital 446 25 1.00
Primary care 149 25 1.01 0.66-1.55 0.967
Coeliac disease in family Yes 372 24 1.00
No 224 25 1.02 0.73-1.57 0.731
Type 1 diabetes mellitus No 582 25 1.00
Yes 14 29 1.23 0.38-3.97 0.735
Thyroid disease No 489 22 1.00
Yes 107 36 2.02 1.29-3.16 0.002
Malignancy No 565 25 1.00
Yes 31 26 1.04 0.47-2.43 0.884
Psychiatric disease No 578 24 1.00
Yes 18 39 1.99 0.76-5.22 0.164
Neurologic disease No 520 24 1.00
Yes 76 30 1.38 0.81-2.35 0.231
Other food intolerance No 470 22 1.00
Yes 126 33 1.74 1.13-2.67 0.012
Other gastrointestinal disease No 388 22 1.00
Yes 208 34 1.80 1.16-2.80 0.009
Any coeliac disease-related co-morbidity No 72 14 1.00
Yes 523 26 2.20 1.10-4.40 0.027
Strict gluten-free diet Yes 523 24 1.00
No 73 27 1.17 0.68-2.04 0.570
Consumption of oats No 105 25 1.00
Yes 487 23 0.87 0.54-1.41 0.568
Duration of diet, years > 10 270 27 1.00
5-10 195 23 0.80 0.51-1.25 0.326
<5 131 25 0.92 0.57-1.42 0.730
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Table 2 Factors associated with persistent gastrointestinal symptoms* in treated coeliac disease patients (Continued)
Professional dietary advice Yes 484 24 1.00
No 112 27 1.15 0.72-1.83 0.564
Regular follow-up Yes 166 25 1.00
No 412 23 0.93 0.61-1.41 0.721
*Defined as a score >1 standard deviation from the mean Gastrointestinal Symptom Rating Scale total score of healthy controls; CI, confidence interval; OR, odds
ratio defined by bivariate logistic regression.
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cant (Table 3). Of note, patients with persistent gastro-
intestinal symptoms were also more likely to have
reduced quality of life (OR 4.66, CI 3.01-7.00, p < 0.001).
The coeliac patients had lower mean PGWB scores than
healthy subjects (p = 0.05).
Discussion
The results of our nationwide study showed that up to
25% of adult coeliac disease patients suffer from persist-
ent gastrointestinal symptoms despite a strict gluten-free
diet. These findings show an excess of gastrointestinal
complaints in treated coeliac patients, although to a
somewhat lesser extent than noted in some previous
studies [23,24]. Yet it needs to be remembered that com-
parison between studies is difficult because both the
methods to measure and definitions used for persistent
symptoms may differ. Further, it is important to distinguish
primary non-responsive patients from those investigated
in the present study; common reasons for non-responsive
coeliac disease are inadvertent gluten intake, refractory
coeliac disease and concomitant diseases such as malig-
nancies, microscopic colitis and pancreatic insufficiency
[5,25,26]. Patients with any such concomitant condition
or refractory coeliac disease were excluded from the
present study. Furthermore, although no histological
evaluation was undertaken here, judging from both
dietary interview and serological testing the majority of
participants were adhering strictly to the diet. It would
thus seem unlikely that inadvertent gluten intake or
presence of the aforesaid adjunct disease would explain
the ongoing gastrointestinal symptoms.
In the present study, coeliac patients diagnosed at
working age had more current symptoms than those
diagnosed at an either younger or older age. Although
we cannot confirm the reason for this age dependency
of the symptoms, it is possible that changes in
established dietary habits are more difficult to cope with
simultaneously with other challenges encountered in
daily work and family life. Likewise, for some unex-
plained reason, irritable bowel syndrome (IBS) often
emerges in early adulthood [27]. Interestingly, also
severe and long-lasting symptoms prior to diagnosis
predispose coeliac patients to persistent symptoms. It
has been suggested that such long-lasting abdominalcomplaints result in a chronic cycle of pain in conse-
quence of changes in the gut-brain axis [28,29]. Of note,
similar chronic alterations have been hypothesized to be
involved in the pathogenesis of IBS, which often co-
exists with coeliac disease [30-32]. There is also evidence
suggesting that the symptoms in IBS might be caused by
continuous low-grade small-bowel mucosal inflamma-
tion [30,31,33], a condition which may persist in coeliac
disease despite a strict gluten-free diet [34,35]. Finally,
small-intestinal bacterial overgrowth may account for
symptoms in both coeliac disease and IBS and is also ac-
companied by mucosal inflammation [33,36,37]. What-
ever mechanisms lie behind the persistent symptoms,
our results indicate that they could be ameliorated by
diagnosing coeliac disease as early as possible.
The results obtained showed the presence of a coeliac
disease-related co-morbidity, another gastrointestinal
disorder or non-coeliac food intolerance to predispose
to persistent symptoms. It is possible that concomitant
gastrointestinal co-morbidity further reinforces the im-
pact of the aforementioned long-lasting changes in the
gut-brain axis. Interestingly, a particular association was
seen between persistent symptoms and concomitant thy-
roid disease, which when untreated is known to may
cause abdominal complaints, these usually recovering on
treatment [38]. However, some patients evince persistent
clinical symptoms and reduced health-related quality of
life even while on treatment and euthyroid [39]. The
pathogenic mechanisms underlying this remain unclear,
but clearly the possible connection between thyroid dis-
ease and persistent gastrointestinal symptoms in coeliac
disease calls for further investigation.
As was the case with gastrointestinal symptoms, a sub-
stantial proportion of the coeliac patients here showed re-
duced health-related quality of life while on a gluten-free
diet. Again, long duration of symptoms before diagnosis
was a predisposing factor. In contrast, there was no associ-
ation between clinical manifestations of coeliac disease at
diagnosis and current quality of life. This is in line with our
previous results showing similar health-related quality of life
in screen-detected and symptom-detected coeliac patients
on a gluten-free diet [12,13]. These findings constitute fur-
ther evidence that early detection and dietary treatment of
coeliac disease is beneficial even in screen-detected patients
with mild or atypical symptoms at diagnosis.
Table 3 Factors associated with persistently reduced quality of life* in treated coeliac disease patients
Variable n Reduced, % OR 95% CI p-value
Gender Male 144 24 1.00
Female 452 25 1.07 0.69-1.67 0.777
Present age, years < 25 12 10 1.00
25-60 380 26 3.21 0.40-25.66 0.272
> 60 204 21 2.40 0.30-19.51 0.413
Age at diagnosis, years < 25 79 25 1.00
25-60 457 25 0.97 0.56-1.68 0.911
> 60 60 22 0.82 0.37-1.81 0.617
Symptoms at diagnosis Gastrointestinal 410 26 1.00
Extraintestinal 95 19 0.65 0.37-1.14 0.136
Screen-detected 91 22 0.79 0.46-1.36 0.389
Duration of symptoms before diagnosis, years No symptoms 37 8 1.00
≤ 10 350 24 3.58 1.07-11.95 0.038
> 10 182 28 4.41 1.30-15.01 0.017
Severity of symptoms at diagnosis No symptoms 62 18 1.00
Moderate 457 26 1.61 0.81-3.20 0.170
Severe 77 22 1.31 0.56-3.06 0.527
Site of diagnosis Hospital 446 25 1.00
Primary care 149 24 0.97 0.63-1.50 0.902
Coeliac disease in family Yes 372 25 1.00
No 224 24 0.97 0.66-1.42 0.864
Type 1 diabetes mellitus No 582 25 1.00
Yes 14 21 0.84 0.23-3.04 0.785
Thyroid disease No 489 24 1.00
Yes 107 25 1.05 0.65-1.70 0.845
Malignancy No 565 25 1.00
Yes 31 13 0.44 0.15-1.28 0.132
Psychiatric disease No 578 23 1.00
Yes 18 67 6.63 2.44-17.99 <0.001
Neurologic disease No 520 23 1.00
Yes 76 33 1.62 0.96-2.72 0.070
Other food intolerance No 470 24 1.00
Yes 126 28 1.24 0.80-1.94 0.335
Other gastrointestinal disease No 388 23 1.00
Yes 208 32 1.56 1.00-2.45 0.052
Any coeliac disease-related co-morbidity No 72 26 1.00
Yes 523 24 0.89 0.51-1.56 0.691
Strict gluten-free diet Yes 523 24 1.00
No 73 27 1.19 0.69-2.07 0.539
Consumption of oats No 105 22 1.00
Yes 487 25 1.19 0.72-1.98 0.497
Duration of diet, years > 10 270 23 1.00
5-10 195 23 0.96 0.61-1.52 0.875
<5 131 29 1.35 0.84-2.18 0.221
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Table 3 Factors associated with persistently reduced quality of life* in treated coeliac disease patients (Continued)
Professional dietary advice Yes 484 24 1.00
No 112 28 1.23 0.77-1.95 0.385
Regular follow-up Yes 166 24 1.00
No 412 24 1.00 0.65-1.52 0.986
*Defined as a score >1 standard deviation from the mean Psychological General Well-Being total score of healthy controls; CI, confidence interval; OR, odds ratio
defined by bivariate logistic regression.
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quality of life and the presence of psychiatric co-
morbidities in our study patients. This is in accord with
some previous findings and there is also evidence that
such coeliac patients might benefit from intensified
psychological counseling [8,18,40-42]. Consequently,
health-care professionals should pay particular attention
to this patient group, who may need special support with
their dietary treatment [42]. Since in the present study
78% of participants with a psychiatric disorder suffered
from depression, the role of other psychiatric disorders
needs further investigation. Although not statistically
significant, there was a trend suggesting that the pres-
ence of certain other co-morbidities, for example neuro-
logical disorders, other gastrointestinal diseases or
non-coeliac food intolerance are factors predisposing
to reduced quality of life in coeliac disease. Further
studies are warranted to clarify the significance of
these issues.
A major strength of our study was a large study cohort
with well-defined coeliac disease diagnoses and clinical
data. In addition, there were a substantial number of
screen-detected patients and subjects with extraintestinal
presentation of coeliac disease. A possible limitation, on
the other hand, was that a substantial proportion of the
participants were recruited through local or national
coeliac disease associations, which might have caused
some selection bias. Furthermore, our participants showed
excellent adherence to the gluten-free diet, this however
being in accord with our earlier findings [12]. Although
good adherence is beneficial for the patient, in this study
it might have concealed the association between poor ad-
herence and reduced quality of life. As a consequence,
results may be different in countries where adherence to a
gluten-free diet is lower. Although the threshold value of
1 SD to define increased symptoms and reduced quality of
life has also been used in other studies, it is somewhat
artificial. The fact that healthy controls were not precisely
matched with the study participants was also a limitation.
The majority of participants used oats as a regular part
of their diet, and this was not associated with increased
gastrointestinal symptoms or reduced quality of life. This
is important, since the use of oat-containing products in
coeliac disease has hitherto remained controversial [43].
Based on our previous results [44] and the findings here,purified oats could be a regular part of a gluten-free diet.
One important issue which should be considered in
evaluating gastrointestinal symptoms in coeliac patients
is that commercial gluten-free products may have
marked qualitative differences, for example in the use of
additives and preservatives and the amount of fibre [45].
Conclusions
As a conclusion, we showed that many coeliac disease
patients suffer from persistent gastrointestinal symptoms
and reduced quality of life despite strict dietary treat-
ment. In particular, long-lasting and severe symptoms
before the diagnosis and concomitant thyroid, gastro-
intestinal and psychiatric co-morbidities were significant
risk factors for these ongoing health concerns. The re-
sults emphasize the importance of early diagnosis and
careful follow-up in coeliac disease.
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